 "More Covid-19 vaccine candidates get approval for clinical trials in India")
A bunch of Covid-19 vaccine candidates got approval from the expert panel to conduct clinical trials in India, including one from Novavax, Bharat Biotech’s intra-nasal candidate, and a measles vector-based candidate from Zydus Cadila.
In its February 3 meeting, the subject expert panel (SEC) advising the Central Drugs Standard Control Organisation (CDSCO) recommended that approval be granted for conducting phase II/III clinical trials to Serum Institute of India (SII) for the Novavax candidate. This vaccine is based on protein nanoparticle and uses the proprietary Matrix-M adjuvant from Novavax. Adjuvants are pharmacological or immunological agents that improve the immune response of a vaccine.
The SEC has noted that participants randomised in the placebo arm may be un-blinded 60 days after the second dose, upon request from the clinical trial participant only. Blinded vaccine trials are those where the participant, investigator and sponsor do not know whether a person was given a vaccine or a placebo.
As for Bharat Biotech’s chimpanzee flu virus (adenovirus) based intra-nasal vaccine candidate, the SEC recommended grant of permission for phase I trials.
Ahmedabad-based Zydus Cadila got approval for conducting phase I/II trials for the 2019-nCoV vaccine 3mg (two dose schedule). The SEC has noted that safety should be the primary objective of the study.
This is Zydus Cadila’s second vaccine candidate, developed by its European research arm Etna Biotech. It is a live weakened recombinant measles virus vector-based vaccine against Covid-19. The genetically engineered measles virus vector would express proteins of the novel coronavirus and, thus, induce long-term specific neutralising antibodies.
Meanwhile, Aurobindo Pharmaceuticals has been asked to submit a revised clinical trial protocol for its vaccine candidate UB-612. The firm presented animal study and phase I data before the committee. The SEC recommended that Aurobindo submit the phase II/III clinical trial protocols approved by the regulatory authority of Brazil and some other conditions.
In its February 3 meeting, the subject expert panel (SEC) advising the Central Drugs Standard Control Organisation (CDSCO) recommended that approval be granted for conducting phase II/III clinical trials to Serum Institute of India (SII) for the Novavax candidate. This vaccine is based on protein nanoparticle and uses the proprietary Matrix-M adjuvant from Novavax. Adjuvants are pharmacological or immunological agents that improve the immune response of a vaccine.
The SEC has noted that participants randomised in the placebo arm may be un-blinded 60 days after the second dose, upon request from the clinical trial participant only. Blinded vaccine trials are those where the participant, investigator and sponsor do not know whether a person was given a vaccine or a placebo.
As for Bharat Biotech’s chimpanzee flu virus (adenovirus) based intra-nasal vaccine candidate, the SEC recommended grant of permission for phase I trials.
Ahmedabad-based Zydus Cadila got approval for conducting phase I/II trials for the 2019-nCoV vaccine 3mg (two dose schedule). The SEC has noted that safety should be the primary objective of the study.
This is Zydus Cadila’s second vaccine candidate, developed by its European research arm Etna Biotech. It is a live weakened recombinant measles virus vector-based vaccine against Covid-19. The genetically engineered measles virus vector would express proteins of the novel coronavirus and, thus, induce long-term specific neutralising antibodies.
Meanwhile, Aurobindo Pharmaceuticals has been asked to submit a revised clinical trial protocol for its vaccine candidate UB-612. The firm presented animal study and phase I data before the committee. The SEC recommended that Aurobindo submit the phase II/III clinical trial protocols approved by the regulatory authority of Brazil and some other conditions.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%